Edwards Lifesciences Corp (NYSE:EW) Stock Holdings Increased by GWM Advisors LLC

GWM Advisors LLC raised its holdings in shares of Edwards Lifesciences Corp (NYSE:EW) by 34.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,408 shares of the medical research company’s stock after acquiring an additional 864 shares during the period. GWM Advisors LLC’s holdings in Edwards Lifesciences were worth $630,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. FTB Advisors Inc. acquired a new stake in Edwards Lifesciences during the first quarter valued at $25,000. TRUE Private Wealth Advisors acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $26,000. Evolution Wealth Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $29,000. M&R Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at approximately $29,000. Finally, Next Capital Management LLC raised its position in shares of Edwards Lifesciences by 297.7% in the second quarter. Next Capital Management LLC now owns 171 shares of the medical research company’s stock valued at $32,000 after buying an additional 128 shares in the last quarter. 81.90% of the stock is currently owned by hedge funds and other institutional investors.

In other news, VP Donald E. Bobo, Jr. sold 3,000 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $169.60, for a total transaction of $508,800.00. Following the transaction, the vice president now owns 20,674 shares in the company, valued at $3,506,310.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William J. Phd Link sold 10,214 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $221.86, for a total transaction of $2,266,078.04. Following the transaction, the director now owns 16,817 shares in the company, valued at approximately $3,731,019.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 148,165 shares of company stock worth $29,342,318. 1.63% of the stock is owned by company insiders.

A number of equities research analysts have recently weighed in on EW shares. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $210.00 to $228.00 and gave the company an “overweight” rating in a research report on Wednesday, July 24th. Jefferies Financial Group lifted their price target on shares of Edwards Lifesciences from $210.00 to $245.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Credit Suisse Group lifted their price target on shares of Edwards Lifesciences from $221.00 to $226.00 and gave the company an “outperform” rating in a research report on Wednesday, July 24th. BTIG Research reiterated a “hold” rating on shares of Edwards Lifesciences in a research report on Thursday, July 25th. Finally, Canaccord Genuity lifted their price target on shares of Edwards Lifesciences from $215.00 to $250.00 and gave the company a “buy” rating in a research report on Wednesday, July 24th. Two analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have issued a buy rating to the company’s stock. Edwards Lifesciences currently has a consensus rating of “Buy” and an average price target of $204.74.

NYSE:EW traded down $1.00 during mid-day trading on Thursday, reaching $220.79. The stock had a trading volume of 4,932 shares, compared to its average volume of 1,149,318. The stock has a 50-day simple moving average of $205.57 and a two-hundred day simple moving average of $186.19. The stock has a market capitalization of $45.97 billion, a PE ratio of 47.03, a P/E/G ratio of 2.80 and a beta of 0.87. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.38 and a quick ratio of 2.48. Edwards Lifesciences Corp has a 12 month low of $136.44 and a 12 month high of $226.41.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.05. The business had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The firm’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same period last year, the firm posted $1.24 earnings per share. Equities analysts expect that Edwards Lifesciences Corp will post 5.34 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Story: When can a hold rating present a buying opportunity?

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.